We're the Strategic Meeting Point for the Next Wave of Obesity Drug Development
The 4th Obesity & Weight Loss Drug Development Summit is designed specifically for biotech and pharma leaders navigating the next frontier of metabolic medicine.
Unlike larger obesity congresses focused primarily on clinical readouts, this summit delivers a highly curated, industry-led environment centered around strategic drug development discussions, meaningful networking, and practical solutions for advancing next-generation obesity therapies.
With 25+ expert speakers from Novo Nordisk, Eli Lilly, Roche, Merck, Veru, Canary Cure, CORXEL Pharmaceuticals, Energesis Pharmaceuticals, and more, the meeting focuses on the biggest strategic challenges shaping the future of obesity drug development, from regulatory strategy and trial design to muscle-preserving therapies, oral obesity drugs, and long-term metabolic health.
"The small meeting format and highly organized networking element was an unusual and highly appreciated feature of the meeting." - Congruence Therapeutics
Why Attend?
While other meetings provide broad scientific updates, the Obesity & Weight Loss Drug Development Summit is intentionally built as a smaller, more strategic forum focused on the practical realities of obesity drug development.
Attendees value the opportunity to network directly with 80+ decision-makers, peers, competitors, and future partners in a more intimate environment that encourages meaningful conversations beyond headline clinical data. Discussions focus on what obesity data actually means for future pipelines, differentiation strategies, regulatory pathways, long-term adherence, and commercialization.
The summit is also uniquely positioned around the “second wave” of obesity innovation, with dedicated discussions on:
- Triple & multi-agonist therapies
- siRNA & RNA therapeutics
- Thermogenic & adipose-targeting approaches
- Muscle-preserving therapies
- Oral obesity therapeutics
- Precision medicine & biomarker-driven development
- Long-term maintenance & rebound prevention
- Functional outcomes beyond weight loss
As the market becomes increasingly crowded, the summit helps companies understand how to differentiate beyond first-generation GLP-1 efficacy toward durable metabolic health and sustainable competitive advantage.
"More informative and targeted than most scientific summits. Smaller setting made collaborating easier." - Cecelia Health
Audience Breakdown*
31%
Director/Head
28%
C-Suite
15%
President/VP
10%
Scientist/Investigator
Company Types Represented*
57%
Drug Developers
40%
Equipment & Service Providers
3%
Research Institutes
Which Companies Are in Attendance?
Who is this Event Designed For?
This summit is built for leaders across obesity and metabolic disease drug development, including experts in GLP-1 and incretin biology, RNA therapeutics, adipose biology, muscle preservation, oral obesity therapeutics, translational medicine, clinical development, regulatory affairs, and commercialization strategy.
Typical attendees include CEOs, CSOs, CMOs, Heads of Obesity & Metabolic R&D, Clinical and Translational Scientists, Regulatory Leaders, Business Development Teams, Investors, and Strategic Partners.
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.